Tag Archive | "orphan diseases"

Orphan Diseases Partnering Terms and Agreements

Tags: ,


The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in orphan diseases partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Orphan diseases partnering contract documents
  • Top orphan diseases deals by value

 

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest orphan diseases agreements announced in the healthcare sector.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all orphan diseases partnering deals announced since 2009 including financial terms where available including over 90 links to online deal records of actual orphan diseases partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of orphan diseases dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in orphan diseases dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

 

Chapter 3 provides a review of the leading orphan diseases deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of orphan diseases deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides comprehensive access to all orphan diseases deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive directory of all orphan diseases partnering deals by specific therapeutic indication announced since 2009. The chapter is organized by specific orphan diseases therapeutic indication. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products.

 

Report scope

 

Orphan Diseases Partnering Terms and  Agreements is intended to provide the reader with an in-depth understanding and access to orphan diseases trends and structure of deals entered into by leading companies worldwide.

 

Orphan Diseases Partnering Terms and Agreements includes:

 

  • Trends in orphan diseases dealmaking in the biopharma industry since 2009
  • Analysis of orphan diseases deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to 90 orphan diseases deal records
  • The leading orphan diseases deals by value since 2009

 

In Orphan Drugs Partnering Terms and Agreements, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Ophan Diseases Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 90 orphan diseases  deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Read the full story

Orphan diseases partnering: A lucrative step for drug makers

Tags: , ,


By Shamini Thiagarajan

Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases. Read the full story

NPS Pharmaceuticals: Big biotech partnering trends 2009-2014

Tags: ,


NPS Pharmaceuticals is a US based specialty company. The company mainly focuses its efforts to treat rare diseases worldwide.  Read the full story

NPS Pharmaceuticals – developing and partnering for rare diseases

Tags: ,


NPS Pharmaceuticals is a global pharmaceutical company treating rare diseases specifically focusing upon gastrointestinal and endocrine disorders. Read the full story

Galapagos: Biotechnology Partnering activity 2009-2014

Tags: , , , ,


Galapagos, a clinical stage biotechnology company in the United States, is a joint venture between Crucell and Tibotec. Read the full story

X-chem and Pfizer sign a pharma deal for orphan diseases

Tags: , ,


X-Chem announced a multi-target pharma deal with Pfizer. Read the full story

Biomarin: Relentlessly pursuing early stage science opportunities

Tags: , ,


Biomarin is a fast growing biopharmaceutical company developing treatments for serious unmet medical conditions and rare diseases. Read the full story

Biomarin: M&A activity 2009-2014

Tags: , ,


Biomarin has acquired a few companies in the last five years with its biggest acquisition being the purchase of $134 million of Zacharon Pharmaceuticals. Read the full story